A Conversation Women Wish They’d Had: Understanding the Risk of Breast Cancer Coming Back
For many women, the end of breast cancer treatment is described as a turning point, bringing mixed emotions…
ETH researcher analyses opponents of Swiss national team
From 11 June, countless millions of people will be following the football World Cup in Canada, Mexico and…
Novartis advances RLT innovation and reinforces leadership
Pluvicto® PSMAddition oral presentation to highlight efficacy outcomes by disease volume and de novo/recurrent metastatic hormone-sensitive prostate cancerKisqali®…
Apertus: a fully open, transparent, multilingual language model
In July, EPFL, ETH Zurich, and CSCS announced their joint initiative to build a large language model (LLM).…
ETH Zurich launches the FAIR Coalition – Staffnet
“ETH Zurich is proud to announce the launch of the ETH FAIR Coalition, an institution-wide initiative,” says Annette Oxenius, Vice-President…
ETH Zurich researchers discover new security vulnerability in Intel processors
Breaking through the built-in protective barriers between users, known as privileges, is possible because the permissions for individual…
ETH Zurich researchers uncover vulnerability in confidential cloud environments
Cloud services are in high demand today, offering users the ability to store data on remote servers and…
Informatica deepens Microsoft Fabric tie-up in Switzerland
Informatica has expanded its collaboration with Microsoft by adding support for Microsoft Fabric Open Mirroring to its Intelligent…
ETH students develop tools for the UN
Voting data made transparent “With our prototype, we want to make it easier to see how UN members…
ABB Robotics partners with NVIDIA to deliver industrial-grade physical AI at scale
ABB Robotics has announced it is integrating NVIDIA Omniverse libraries into ABB Robotics’ RobotStudio to help manufacturers deploy…
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR…
Novartis data underscore pioneering scientific innovation in hematology and oncology at ASH and SABCS
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented…